{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:49:05Z","timestamp":1774676945422,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008067","name":"Genomic Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016765","name":"Jounce Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clbc.2020.11.012","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T05:20:35Z","timestamp":1608268835000},"page":"e340-e361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data"],"prefix":"10.1016","volume":"21","author":[{"given":"Louis E.","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6835-7175","authenticated-orcid":false,"given":"Caroline G.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-709X","authenticated-orcid":false,"given":"Alexandria M.","family":"Bobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua S.K.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1402-6749","authenticated-orcid":false,"given":"Martin C.","family":"Stumpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameen A.","family":"Salahudeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth A.","family":"Pe Benito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7257-1350","authenticated-orcid":false,"given":"Calvin","family":"McCarter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0535-5463","authenticated-orcid":false,"given":"Benjamin D.","family":"Leibowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Kase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Igartua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-7470","authenticated-orcid":false,"given":"Robert","family":"Huether","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Hafez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nike","family":"Beaubier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9273-6936","authenticated-orcid":false,"given":"Michael D.","family":"Axelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9743-8118","authenticated-orcid":false,"given":"Mark D.","family":"Pegram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L.","family":"Sammons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce A.","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-1329","authenticated-orcid":false,"given":"Gary A.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2020.11.012_bib1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jamaoncol.2019.0450","article-title":"Real-world evidence\u2014what does it really mean?","volume":"5","author":"Nabhan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2020.11.012_bib2","series-title":"Framework for the FDA\u2019s Real-world Evidence Program","year":"2018"},{"key":"10.1016\/j.clbc.2020.11.012_bib3","article-title":"Susan G. Komen Big Data for Breast Cancer Initiative: how patient advocacy organizations can facilitate using big data to improve patient outcomes","volume":"3","author":"Jourquin","year":"2019","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/j.clbc.2020.11.012_bib4","series-title":"Submitting documents using real-world data and real-world evidence to FDA for drugs and biologics: guidance for industry","year":"2019"},{"key":"10.1016\/j.clbc.2020.11.012_bib5","series-title":"Use of electronic health record data in clinical investigations: guidance for industry","year":"2018"},{"key":"10.1016\/j.clbc.2020.11.012_bib6","series-title":"Use of real-world evidence to support regulatory decision-making for medical devices: guidance for industry and food and drug administration staff","year":"2017"},{"key":"10.1016\/j.clbc.2020.11.012_bib7","doi-asserted-by":"crossref","first-page":"djx187","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world data for clinical evidence generation in oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2020.11.012_bib8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s12325-018-0867-x","article-title":"Clinical outcomes, treatment patterns, and health resource utilization among metastatic breast cancer patients with germline BRCA1\/2 mutation: a real-world retrospective study","volume":"36","author":"Quek","year":"2019","journal-title":"Adv Therapy"},{"key":"10.1016\/j.clbc.2020.11.012_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2018.10.009","article-title":"Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+\/HER2-negative advanced\/metastatic breast cancer in real-world settings in the US: results from the IRIS study","volume":"43","author":"Taylor-Stokes","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2020.11.012_bib10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1634\/theoncologist.2018-0307","article-title":"Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval","volume":"24","author":"Khozin","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2020.11.012_bib11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s13063-018-2769-2","article-title":"The inclusion of real world evidence in clinical development planning","volume":"19","author":"Martina","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.clbc.2020.11.012_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.16.00044","article-title":"Analysis of adjuvant endocrine therapy in practice from electronic health record data of patients with breast cancer","volume":"1","author":"Harrell","year":"2017","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clbc.2020.11.012_bib13","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1200\/JCO.2015.62.0229","article-title":"Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish\u2013Swedish population-based study","volume":"33","author":"El-Galaly","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.11.012_bib14","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2020.11.012_bib15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.7326\/M15-1460","article-title":"The ADAPTABLE trial and PCORnet: shining light on a new research paradigm","volume":"163","author":"Hernandez","year":"2015","journal-title":"Ann Int Med"},{"key":"10.1016\/j.clbc.2020.11.012_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.11.012_bib17","author":"Pfizer"},{"key":"10.1016\/j.clbc.2020.11.012_bib18","series-title":"IBRANCE\u00ae (palbociclib) capsules, for oral use - Label.pdf","year":"2019"},{"key":"10.1016\/j.clbc.2020.11.012_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/jamaoncol.2016.3340","article-title":"Association of adjuvant tamoxifen and aromatase inhibitor therapy with contralateral breast cancer risk among US women\u00a0with breast cancer in a general community setting","volume":"3","author":"Gierach","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2020.11.012_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-018-4804-0","article-title":"Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001\u20132016)","volume":"171","author":"Daniels","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.11.012_bib21","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1002\/cam4.2548","article-title":"Differential impact of cognitive computing augmented by real world evidence on novice and expert oncologists","volume":"8","author":"McNamara","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clbc.2020.11.012_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00392-016-1025-6","article-title":"Electronic health records to facilitate clinical research","volume":"106","author":"Cowie","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.clbc.2020.11.012_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2018.06.036","article-title":"The use of real-world data in cancer drug development","volume":"101","author":"Skovlund","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2020.11.012_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13073-016-0371-3","article-title":"Integrating cancer genomic data into electronic health records","volume":"8","author":"Warner","year":"2016","journal-title":"Genome Med"},{"key":"10.1016\/j.clbc.2020.11.012_bib25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0140-6736(18)31619-2","article-title":"Improving observational studies in the era of big data","volume":"392","author":"Gill","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2020.11.012_bib26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/cpt.946","article-title":"Harnessing the power of real-world evidence (RWE): a checklist to ensure regulatory-grade data quality","volume":"103","author":"Miksad","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clbc.2020.11.012_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00132","article-title":"Real-world evidence and randomized studies in the precision oncology era: the right balance","volume":"1","author":"Gyawali","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clbc.2020.11.012_bib28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","volume":"110","author":"Shimelis","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2020.11.012_bib29","doi-asserted-by":"crossref","first-page":"12184","DOI":"10.1038\/s41598-019-48570-x","article-title":"Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series","volume":"9","author":"Vallon-Christersson","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clbc.2020.11.012_bib30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41416-018-0030-0","article-title":"An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes","volume":"118","author":"Gy\u0151rffy","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.11.012_bib31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fgene.2017.00170","article-title":"HOTAIR: a promising long non-coding RNA with potential role in breast invasive carcinoma","volume":"8","author":"Avazpour","year":"2017","journal-title":"Front Genet"},{"key":"10.1016\/j.clbc.2020.11.012_bib32","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T cells exhibit distinct features in human breast cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.clbc.2020.11.012_bib33","doi-asserted-by":"crossref","first-page":"27931","DOI":"10.1038\/srep27931","article-title":"Transcriptome sequencing uncovers a three\u2013long noncoding RNA signature in predicting breast cancer survival","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clbc.2020.11.012_bib34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/1535-7163.MCT-12-0781","article-title":"Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities","volume":"12","author":"Craig","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clbc.2020.11.012_bib35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1586\/erm.09.25","article-title":"Current molecular diagnostics of breast cancer and the potential incorporation of microRNA","volume":"9","author":"Zoon","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.clbc.2020.11.012_bib37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","article-title":"Integrated genomic profiling expands clinical options for patients with cancer","volume":"37","author":"Beaubier","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"15 Suppl","key":"10.1016\/j.clbc.2020.11.012_bib38","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.2019.37.15_suppl.3081","article-title":"Transcriptome-based cancer type prediction for tumors of unknown origin","volume":"37","author":"Michuda","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.11.012_bib39","doi-asserted-by":"crossref","first-page":"e192597","DOI":"10.1001\/jamanetworkopen.2019.2597","article-title":"Application of a neural network whole transcriptome\u2013based pan-cancer method for diagnosis of primary and metastatic cancers","volume":"2","author":"Grewal","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clbc.2020.11.012_bib40","article-title":"Clinical value of RNA sequencing\u2013based classifiers for prediction of the five conventional breast cancer biomarkers: a report from the population-based multicenter Sweden Cancerome Analysis Network\u2014Breast Initiative","volume":"2","author":"Brueffer","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clbc.2020.11.012_bib41","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1186\/1471-2164-15-1008","article-title":"Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology","volume":"15","author":"Fumagalli","year":"2014","journal-title":"BMC Genomics"},{"key":"10.1016\/j.clbc.2020.11.012_bib42","doi-asserted-by":"crossref","first-page":"25826","DOI":"10.18632\/oncotarget.25381","article-title":"Clinical validation of the Tempus xO assay","volume":"9","author":"Beaubier","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2020.11.012_bib43","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2020.11.012_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-Seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.clbc.2020.11.012_bib45","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"10.1016\/j.clbc.2020.11.012_bib46","unstructured":"American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Available at: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/breast-cancer-facts-and-figures-2019-2020.pdf. Accessed: August 28, 2020."},{"key":"10.1016\/j.clbc.2020.11.012_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2014.17322","article-title":"Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States","volume":"313","author":"Iqbal","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2020.11.012_bib49","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/annonc\/mds330","article-title":"Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole","volume":"24","author":"Goss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.11.012_bib50","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"Desantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2020.11.012_bib51","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/tbj.13236","article-title":"ER\u2212\/PR+\/HER2\u2212 breast cancer type shows the highest proliferative activity among all other combined phenotypes and is more common in young patients: experience with 6643 breast cancer cases","volume":"25","author":"Arena","year":"2019","journal-title":"Breast J"},{"key":"10.1016\/j.clbc.2020.11.012_bib52","doi-asserted-by":"crossref","first-page":"496","DOI":"10.20892\/j.issn.2095-3941.2016.0066","article-title":"Ki-67 as a prognostic marker according to breast cancer molecular subtype","volume":"13","author":"Soliman","year":"2016","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.clbc.2020.11.012_bib53","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41416-018-0114-x","article-title":"Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the \u201cone thousand HER2 patients\u201d project","volume":"119","author":"Gullo","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.11.012_bib54","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s12282-014-0528-0","article-title":"A\u00a0meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer","volume":"22","author":"Bahreini","year":"2015","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2020.11.012_bib55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2020.11.012_bib56","doi-asserted-by":"crossref","first-page":"15180","DOI":"10.1038\/ncomms15180","article-title":"A\u00a0molecular portrait of microsatellite instability across multiple cancers","volume":"8","author":"Cortes-Ciriano","year":"2017","journal-title":"Nat Comm"},{"key":"10.1016\/j.clbc.2020.11.012_bib57","doi-asserted-by":"crossref","first-page":"e0163238","DOI":"10.1371\/journal.pone.0163238","article-title":"Consensus analysis of whole transcriptome profiles from two breast cancer patient cohorts reveals long non-coding RNAs associated with intrinsic subtype and the tumour microenvironment","volume":"11","author":"Bradford","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2020.11.012_bib58","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/srep00264","article-title":"Transcriptomic landscape of breast cancers through mRNA sequencing","volume":"2","author":"Eswaran","year":"2012","journal-title":"Sci Rep"},{"key":"10.1016\/j.clbc.2020.11.012_bib59","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","article-title":"Subtypes of breast cancer show preferential site of relapse","volume":"68","author":"Smid","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2020.11.012_bib60","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13058-016-0725-1","article-title":"Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification","volume":"18","author":"Allott","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2020.11.012_bib61","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10549-018-05119-2","article-title":"Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant","volume":"174","author":"Robertson","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.11.012_bib62","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/annonc\/mds599","article-title":"Reliability of core needle biopsy for determining ER and HER2 status in breast cancer","volume":"24","author":"Dekker","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.11.012_bib63","first-page":"383","article-title":"mTOR function and therapeutic targeting in breast cancer","volume":"7","author":"Hare","year":"2017","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clbc.2020.11.012_bib64","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41523-018-0072-8","article-title":"Is there a role for immunotherapy in HER2-positive breast cancer?","volume":"4","author":"Holgado","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2020.11.012_bib65","first-page":"4984","article-title":"Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer","volume":"16","author":"Wu","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clbc.2020.11.012_bib66","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000331643","article-title":"Triple-negative breast cancer: clinical and histological correlations","volume":"6","author":"Elsawaf","year":"2011","journal-title":"Breast Care"},{"key":"10.1016\/j.clbc.2020.11.012_bib67","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1038\/s41598-019-39789-9","article-title":"2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype","volume":"9","author":"O\u2019Neill","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clbc.2020.11.012_bib68","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2020.11.012_bib69","series-title":"Blueprint for breakthrough: exploring the utility of real world evidence (RWE)","year":"2016"},{"key":"10.1016\/j.clbc.2020.11.012_bib70","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jbi.2016.01.017","article-title":"A\u00a0method for using real world data in breast cancer modeling","volume":"60","author":"Pobiruchin","year":"2016","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.clbc.2020.11.012_bib71","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1007\/s12325-019-00970-1","article-title":"Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer","volume":"36","author":"Griffith","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.clbc.2020.11.012_bib72","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.clgc.2013.05.002","article-title":"\u201cReal world\u201d treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy","volume":"11","author":"Harrison","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clbc.2020.11.012_bib73","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/s41379-019-0295-8","article-title":"Implementation of the 2018 American Society of Clinical Oncology\/College of American Pathologists Guidelines on HER2\/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort","volume":"32","author":"Zare","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2020.11.012_bib74","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.11.012_bib75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4 Suppl","key":"10.1016\/j.clbc.2020.11.012_bib76","first-page":"GS1","volume":"78","author":"Fehrenbacher","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2020.11.012_bib77","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","article-title":"Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b\u20132 trial","volume":"20","author":"Loi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2020.11.012_bib78","first-page":"53","article-title":"Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches","volume":"11","author":"Ayoub","year":"2019","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.clbc.2020.11.012_bib79","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1002\/cncr.26734","article-title":"HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ","volume":"118","author":"Sharma","year":"2012","journal-title":"Cancer"},{"issue":"4 Suppl","key":"10.1016\/j.clbc.2020.11.012_bib80","article-title":"Abstract P3-10-06: Expression-based immune signatures as predictors of neoadjuvant targeted-\/chemo-therapy response: experience from the I-SPY 2 TRIAL of \u02dc1000 patients across 10 therapies","volume":"79","author":"Yau","year":"2019","journal-title":"Cancer Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920302962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920302962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:24:03Z","timestamp":1761513843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820920302962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1526820920302962"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2020.11.012","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.07.20168401","asserted-by":"object"}]},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2020.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}